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Dear Editor,
Substance use and dependence remains a very serious health pro-
blem in developed countries. Therefore, evaluating and monitoring 
the efficacy of substance use treatment programmes has become a 
matter of growing concern. The use of brief and multi-dimensional 
instruments has been indicated as a possible solution1,2, since it allows 
a swift diagnosis of the individual and the services one was provided 
with, enabling the adjustment of the interventions according to the 
users’ needs and comorbidities3-9. In order to evaluate and monitoring 
the efficacy of substance use treatments, a pilot study was undertaken 
for the Portuguese population based on a brief multi-dimensional 
instrument, the Texas Christian University – Client Evaluation of 
Self and Treatment – TCU – CEST1. The choice of this instrument 
was based upon four basic criteria: (a) adequate values of validity 
and fidelity found in the original instrument1, (b) applicability to a 
variety of dependence treatment programmes, (c) wide evaluation 
of the efficacy indicators diversity, and (d) confirmed utility in the 
clinical practice1,10. The instrument is composed of a total of 130 
items that are grouped into four dimensions: (a) motivation for 
treatment, (b) psychological functioning, (c) social functioning, 
and (d) therapeutic process1,4,10. At first, the translation and back-
-translation were done by a bilingual specialist. This was followed 
by the spoken reflection with 30 users aimed at evaluating the items’ 
understanding and adequacy and individual pilot interviews with 8 
professionals of 4 specialties (2 social work assistants, 3 psychologists, 
2 psychiatrists and 1 nurse). As a second step, the questionnaire 
was administered to a convenience sample of 120 users (75% in 
a programme of opioid replacement therapy with methadone), in 
the Centre of Integrated Responses – west Oporto, composed of 
114 men (95%) and 6 women (5%), between the ages of 19 and 56 
(M = 38), and 90% of Portuguese nationality. All the interviewees 
could speak and understand Portuguese. The results suggest that the 
majority of the subscales present regular values of global adjustment 
and acceptable values of internal consistency, as can be seen in the 
dimensions Therapeutic process (GFI = .946-1.0, AGFI = .903-1.0, 
CFI = .967-1.0, RMSEA = .000-.072, α = .684-.888) and Psychological 
functioning (with the exception of the Self-efficacy subscale) (GFI = 
.963-.991, AGFI = .926-.961, CFI = .955-1.0, RMSEA = .000-.055, α 
= .697-.746). Unlike the results reported by Joe et al. (2002)1, some 
subscales present limitations: the dimension Motivation for treat-
ment (GFI = .974-980, AGFI = .916-.941, CFI = .939-979, RMSEA 
= .028-.083, α = .329-.655); and, in terms of internal consistency, 
the subscales Self-efficacy (α = .542), Risky behaviour (α = .665) 
and Social conscience (α = .406). The small size of the sample and 
its specificity (75% in a programme of opioid replacement therapy 
with methadone) may have contributed to the reported results. As so, 
given the inadequacy of some items of the dimension Motivation for 
the treatment, we have suggested the elimination of this dimension 
in future applications of the TCU-CEST – Portuguese version2. The 
results of this study also underscore the need to revising the subscales 
Self-efficacy, Risky behaviour and Social conscience, as to achieve a 
closer cultural adaptation to the Portuguese context. Finally, further 
research should be undertaken in order to assess the validity of the 
instrument TCU-CEST, by examining its adequacy with samples 
of users dependent on other drugs and users in different treatment 
programmes. 
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